What are the performance share units reported by AGIO CFO Cecilia Jones?

The filing shows 3,000 performance share units linked to clinical and research milestones. Each unit corresponds to one share of common stock, with vesting dependent on achieving specified milestones and the executive’s continued service with AGIOS PHARMACEUTICALS.

When will the AGIO performance share units related to the research milestone vest?

The shares underlying the 3,000 performance share units linked to the research milestone are scheduled to vest on December 31, 2027. Vesting is conditioned on the milestone criteria being met and Cecilia Jones’s continued service through that date.

What milestone triggered the performance determination for AGIO’s performance share units?

The performance criteria for a specified research milestone were determined to be met as of June 18, 2026. This determination relates to performance share units whose vesting depends on achieving clinical and research milestones set by AGIOS’s compensation & people committee.

AGIOS CFO granted 3,000 RSUs and milestone PSUs

Q: When were the performance share units for AGIO’s CFO originally granted?

The performance share units were granted on March 1, 2025. They were structured to vest based on three specified clinical and research milestones determined by AGIOS’s compensation & people committee or its board of directors, as applicable.

Jones Cecilia reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jones Cecilia reported acquisition or exercise transactions in this Form 4 filing.

AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported equity compensation activity involving restricted stock units and performance share units. She received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. A separate award of 3,000 performance share units tied to a specified research milestone had its performance criteria determined to be met as of June 18, 2026. The underlying shares for this milestone are scheduled to vest on December 31, 2027, subject to her continued service.

Insider Trade Summary

3,000 shares exercised/converted

Exercise 2 txns

Insider Jones Cecilia

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Performance share units	3,000	$0.00	$0.00
Grant/Award	Restricted stock units	3,000	$0.00	$0.00

Holdings After Transaction: Performance share units — 9,000 contracts (Direct); Restricted stock units — 3,000 contracts (Direct)

Footnotes (3)

F1. Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
F3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Key Figures

Restricted stock units granted: 3,000 units Performance share units tied to milestone: 3,000 units Vesting date for milestone-related shares: December 31, 2027 +2 more

5 metrics

Restricted stock units granted 3,000 units Grant of restricted stock units to CFO on June 18, 2026

Performance share units tied to milestone 3,000 units Performance criteria determined met as of June 18, 2026

Vesting date for milestone-related shares December 31, 2027 Scheduled vesting for shares underlying the research milestone PSUs

Total derivative transaction count 2 transactions Form 4 derivative-type entries for RSUs and PSUs

Performance units exercisable into common stock 1 unit = 1 share Each performance share unit represents a right to one common share

Key Terms

Restricted stock units, Performance share units, contingent right, clinical and research milestones, +1 more

5 terms

Restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."

clinical and research milestones financial

"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones"

compensation & people committee financial

"milestones established by the compensation & people committee, or board of directors, as applicable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AGIO CFO Cecilia Jones report in this Form 4 transaction?

Cecilia Jones reported equity compensation activity, including 3,000 restricted stock units and 3,000 performance share units. Both instruments represent contingent rights to AGIOS common stock, reflecting non-cash compensation rather than open-market share purchases or sales.

How many restricted stock units did AGIO grant to its CFO Cecilia Jones?

Cecilia Jones received a grant of 3,000 restricted stock units. Each unit represents a contingent right to receive one share of AGIOS PHARMACEUTICALS common stock, aligning part of her compensation with the company’s future share performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:14 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Cecilia

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance share units	⁽¹⁾	06/18/2026		M			3,000	⁽²⁾	⁽²⁾	Common stock	3,000	$0	9,000	D
Restricted stock units	⁽³⁾	06/18/2026		A		3,000		⁽²⁾	⁽²⁾	Common stock	3,000	$0	3,000	D

Explanation of Responses:

1. Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.

2. Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ William Cook, as attorney-in-fact for Cecilia Jones	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR